Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart diseaseN Engl J Med, 354
(2004)
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemiaAtherosclerosis, 173
(2013)
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trialJ Am Coll Cardiol, 62
(2014)
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trialJAMA, 311
(2009)
The LDL receptorArterioscler Thromb Vasc Biol, 29
(2012)
Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapyCirculation, 125
(2012)
Guidelines for the management of familial hypercholesterolemiaJ Atheroscler Thromb, 19
(2011)
ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Eur Heart J, 32
(Civeira F, Ros E, Jarauta E, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008;102:1187–93, 93 e1.)
Civeira F, Ros E, Jarauta E, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008;102:1187–93, 93 e1.Civeira F, Ros E, Jarauta E, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008;102:1187–93, 93 e1., Civeira F, Ros E, Jarauta E, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008;102:1187–93, 93 e1.
(2002)
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemiaCirculation, 105
(1985)
Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchangeBr Med J (Clin Res Ed), 291
(2010)
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterolJ Lipid Res, 51
(Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303:893–6.)
Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303:893–6.Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303:893–6., Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303:893–6.
(2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trialLancet, 375
(2013)
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 studyLancet, 381
(2014)
Effects of extended-release niacin with laropiprant in high-risk patientsN Engl J Med, 371
(2011)
Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapyCirculation, 124
(2007)
A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterolArterioscler Thromb Vasc Biol, 27
(2011)
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med, 365
(2010)
Low-density lipoprotein apheresis using double filtration plasmapheresis: 27-month use in a child with homozygous familial hypercholesterolemiaTher Apher Dial, 14
(2013)
Diagnosis and treatment of familial hypercholesterolaemiaEur Heart J, 34
(2012)
Molecular characterization of familial hypercholesterolemia in SpainAtherosclerosis, 221
(2013)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis SocietyEur Heart J, 34
(2014)
Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statinsNat Commun, 5
(2004)
Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence reviewAm J Epidemiol, 160
(2008)
Familial hypercholesterolaemia: summary of NICE guidanceBMJ, 337
(IMPROVE-IT Trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. 2014. Available from: http://my.americanheart.org/professional/Sessions/ScientificSessions/ScienceNews/SS14-Late-Breaking-Clinical-Trials_UCM_468855_Article.jsp. Accessed 3 Mar 2015.)
IMPROVE-IT Trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. 2014. Available from: http://my.americanheart.org/professional/Sessions/ScientificSessions/ScienceNews/SS14-Late-Breaking-Clinical-Trials_UCM_468855_Article.jsp. Accessed 3 Mar 2015.IMPROVE-IT Trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. 2014. Available from: http://my.americanheart.org/professional/Sessions/ScientificSessions/ScienceNews/SS14-Late-Breaking-Clinical-Trials_UCM_468855_Article.jsp. Accessed 3 Mar 2015., IMPROVE-IT Trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. 2014. Available from: http://my.americanheart.org/professional/Sessions/ScientificSessions/ScienceNews/SS14-Late-Breaking-Clinical-Trials_UCM_468855_Article.jsp. Accessed 3 Mar 2015.
(1997)
Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemiaAtherosclerosis, 135
(2010)
PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analysesJ Am Coll Cardiol, 55
(2006)
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapyArterioscler Thromb Vasc Biol, 26
(In: Identification and management of familial hypercholesterolaemia (FH). London; 2008.)
In: Identification and management of familial hypercholesterolaemia (FH). London; 2008.In: Identification and management of familial hypercholesterolaemia (FH). London; 2008., In: Identification and management of familial hypercholesterolaemia (FH). London; 2008.
(Schaefer JR, Kurt B, Sattler A, Klaus G, Soufi M. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R). Clin Res Cardiol Suppl 2012;7:2–6.)
Schaefer JR, Kurt B, Sattler A, Klaus G, Soufi M. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R). Clin Res Cardiol Suppl 2012;7:2–6.Schaefer JR, Kurt B, Sattler A, Klaus G, Soufi M. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R). Clin Res Cardiol Suppl 2012;7:2–6., Schaefer JR, Kurt B, Sattler A, Klaus G, Soufi M. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R). Clin Res Cardiol Suppl 2012;7:2–6.
(1995)
A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemiaNat Med, 1
(2014)
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesCirculation, 129
(2014)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialLancet, 385
(2014)
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialLancet, 385
(2008)
Efficacy of statins in familial hypercholesterolaemia: a long term cohort studyBMJ, 337
(2014)
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patientsBMJ, 349
JKHH Goldstein, MS Brown (2001)
Familial hypercholesterolemia
(2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet, 366
(2007)
Colesevelam: a review of its use in hypercholesterolemiaAm J Cardiovasc Drugs, 7
(2013)
Italian multicenter study on low-density lipoprotein apheresis Working Group 2009 surveyTher Apher Dial, 17
(2008)
A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemiaAtherosclerosis, 197
(2010)
Beyond LDL cholesterol, a new role for PCSK9Arterioscler Thromb Vasc Biol, 30
(1999)
Fibrates, dyslipoproteinaemia and cardiovascular diseaseCurr Opin Lipidol, 10
(1976)
A new approach to the management of familial hypercholesterolaemia: removal of plasma-cholesterol based on the principle of affinity chromatographyLancet, 1
(Kynamro (mipomersen sodium). 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002429/human_med_001622.jsp&mid=WC0b01ac058001d124. Accessed 16 Oct 2014.)
Kynamro (mipomersen sodium). 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002429/human_med_001622.jsp&mid=WC0b01ac058001d124. Accessed 16 Oct 2014.Kynamro (mipomersen sodium). 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002429/human_med_001622.jsp&mid=WC0b01ac058001d124. Accessed 16 Oct 2014., Kynamro (mipomersen sodium). 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002429/human_med_001622.jsp&mid=WC0b01ac058001d124. Accessed 16 Oct 2014.
(2014)
Integrated guidance on the care of familial hypercholesterolaemia from the International FH FoundationInt J Cardiol, 171
(2003)
Living-donor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemiaTranspl Int, 16
(2011)
Liver transplantation as treatment for familial homozygous hypercholesterolemia: too early or too latePediatr Transplant, 15
(2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trialsLancet, 376
(2014)
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumabJ Am Coll Cardiol, 63
(2006)
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosisPharmacol Rev, 58
(2013)
Use of niacin in the United States and CanadaJAMA Intern Med, 173
(1964)
The inheritance of essential familial hypercholesterolemiaAm J Med, 37
(1981)
Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemiaLancet, 2
(2013)
Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemiaHuman Gene Ther Clin Dev, 24
(2012)
Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FHCirc Cardiovasc Genet, 5
(2014)
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumabJ Am Coll Cardiol, 63
(2012)
Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medicationJ Clin Endocrinol Metab, 97
(1990)
Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytesProc Natl Acad Sci USA, 87
(1998)
Mechanism of action of fibrates on lipid and lipoprotein metabolismCirculation, 98
(1984)
Heart-liver transplantation in a patient with familial hypercholesterolaemiaLancet, 1
(1993)
Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular geneticsAm J Cardiol, 72
(2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNat Genet, 34
(1967)
Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis ans heroic treatmentBull Soc Med Hop Paris, 118
(2014)
Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemiaCirculation, 129
(2014)
A 52-week placebo-controlled trial of evolocumab in hyperlipidemiaN Engl J Med, 370
(1987)
Archives of internal medicine, volume 64, October 1939: angina pectoris in hereditary xanthomatosis. By Carl MullerNutr Rev, 45
(1992)
Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemiaScience, 258
(2013)
Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1Arterioscler Thromb Vasc Biol, 33
(2014)
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis SocietyEur Heart J, 35
Familial hypercholesterolemia (FH) is an inherited disorder of lipid metabolism characterized by premature cardiovascular disease. It is one of the most common metabolic disorders affecting humans. There are two clinical manifestations: the milder heterozygous form and more severe homozygous form. Despite posing a significant health risk, FH is inadequately diagnosed and managed. As the clinical outcome is related to the degree and duration of exposure to elevated low-density lipoprotein cholesterol (LDL-C) levels, early treatment is vital. Diagnosis can usually be made using a combination of clinical characteristics such as family history, lipid levels, and genetic testing. Mutations in the gene encoding the LDL receptor (LDLR), apolipoprotein B, the pro-protein convertase subtilisin/kexin 9 (PCSK9), and LDLR adaptor protein are the commonest abnormalities. Early identification and treatment of patients, as well as screening of relatives, helps significantly reduce the risk of premature disease. Although statins remain the first-line therapy in most cases, monotherapy is usually inadequate to control elevated LDL-C levels. Additional therapy with ezetimibe and bile acid sequestrants may be required. Newer classes of pharmacotherapy currently under investigation include lomitapide, mipomersen, and monoclonal antibodies to PCSK9. Lipoprotein apheresis may be required when multiple pharmacotherapies are inadequate, especially in the homozygous form. Effective early detection and treatment of the index individual and initiation of cascade screening will help reduce the complications associated with FH. In this article, we review the disease of FH, complexity of diagnosis and management, and the challenges faced in preventing the significant morbidity and mortality associated with it.
Cardiology and Therapy – Springer Journals
Published: Mar 14, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.